Alector, Inc. (ALEC)

NASDAQ: ALEC · Real-Time Price · USD
1.295
-0.075 (-5.47%)
Mar 25, 2025, 4:00 PM EST - Market closed
-5.47%
Market Cap 127.82M
Revenue (ttm) 100.56M
Net Income (ttm) -119.05M
Shares Out 99.09M
EPS (ttm) -1.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 536,164
Open 1.350
Previous Close 1.370
Day's Range 1.270 - 1.360
52-Week Range 1.260 - 6.780
Beta 0.65
Analysts Buy
Price Target 4.10 (+216.6%)
Earnings Date May 7, 2025

About ALEC

Alector, Inc., a late-stage clinical biotechnology company, develops therapies that is focused on counteracting the devastating progression of neurodegenerative diseases. The company’s products under development include Latozinemab (AL001), an investigational human recombinant monoclonal antibody designed to elevate progranulin (PGRN), a protein encoded by the granulin (GRN) gene that regulates lysosomal function, neuronal survival, and inflammation in the brain. Its lead PGRN-elevating candidate is being developed for the potential treatment o... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 7, 2019
Employees 238
Stock Exchange NASDAQ
Ticker Symbol ALEC
Full Company Profile

Financial Performance

In 2024, Alector's revenue was $100.56 million, an increase of 3.60% compared to the previous year's $97.06 million. Losses were -$119.05 million, -8.70% less than in 2023.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for ALEC stock is "Buy." The 12-month stock price forecast is $4.1, which is an increase of 216.60% from the latest price.

Price Target
$4.1
(216.60% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Alector, Inc. (ALEC) Q4 2024 Earnings Call Transcript

Alector, Inc. (NASDAQ:ALEC) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Katie Hogan - Senior Director-Corporate Communications and Investor Relations Arnon Rose...

26 days ago - Seeking Alpha

Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Anticipate completing enrollment in the PROGRESS-AD Phase 2 clinical trial of AL101/GSK 452...

27 days ago - GlobeNewsWire

Alector to Participate in Upcoming Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating p...

4 weeks ago - GlobeNewsWire

Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating p...

4 weeks ago - GlobeNewsWire

Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025

Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company's commitment to developing genetically-validated th...

2 months ago - GlobeNewsWire

Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts

Bank of America Securities has downgraded Alector, Inc.  ALEC, citing the failure of its AL002 program.

3 months ago - Benzinga

Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce

On Monday, Alector, Inc.  ALEC released results from the INVOKE-2 Phase 2 trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease...

4 months ago - Benzinga

Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment ...

4 months ago - GlobeNewsWire

Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the Company has en...

4 months ago - GlobeNewsWire

Alector Reports Third Quarter 2024 Financial Results and Provides Business Update

Data from INVOKE-2, evaluating TREM2 agonist candidate AL002 in patients with early Alzheimer's disease (AD), on track for 2024

4 months ago - GlobeNewsWire

Alector, Inc. (ALEC) Q2 2024 Earnings Call Transcript

Alector, Inc. (NASDAQ:ALEC) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Katie Hogan – Senior Director-Corporate Communications and Investor Relations Arnon Rosenth...

8 months ago - Seeking Alpha

Alector Reports Second Quarter 2024 Financial Results and Provides Business Update

Data from INVOKE-2 Phase 2 clinical trial of AL002 in individuals with early Alzheimer's disease (AD) on track for Q4 2024

8 months ago - GlobeNewsWire

Alector to Host Mid-Year Earnings Conference Call

Call Scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT Call Scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT

8 months ago - GlobeNewsWire

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

--INVOKE-2 is the first global Phase 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer's disease (AD)-- --Baselin...

8 months ago - GlobeNewsWire

Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024

SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related t...

8 months ago - GlobeNewsWire

Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform

Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation Leading scientific expert to provide insights into emerging technologies for blood-brain bar...

10 months ago - GlobeNewsWire

Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript

Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript

1 year ago - Seeking Alpha

Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer's disease (AD), expected in Q4 2024; trial enrollment completed in Q3 2023

1 year ago - GlobeNewsWire

Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call

Call Scheduled for Tuesday, February 27, 2024, at 4:30 p.m. ET/1:30 p.m. PT Call Scheduled for Tuesday, February 27, 2024, at 4:30 p.m. ET/1:30 p.m. PT

1 year ago - GlobeNewsWire

Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's Disease

The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globally The trial, being conducted in partnership with GSK, is expected to enroll approximately 28...

1 year ago - GlobeNewsWire

FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

-Latozinemab is the most advanced progranulin-elevating candidate in development for FTD-GRN and has now become the first investigational medicine to receive a Breakthrough Therapy Designation for the...

1 year ago - GlobeNewsWire

Alector Announces Closing of Public Offering

SOUTH SAN FRANCISCO, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the closing of its unde...

1 year ago - GlobeNewsWire

Alector: Q4 2024 Data Release Could Provide Major Shift For Valuation

Alector, Inc. expects results from its phase 2 INVOKE-2 study, using AL002 for the treatment of patients with Alzheimer's disease, in Q4 of 2024. IND clearance received to begin a phase 2 study using ...

1 year ago - Seeking Alpha

Alector Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the pricing of an under...

1 year ago - GlobeNewsWire

Alector Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it intends to offe...

1 year ago - GlobeNewsWire